Risk and main contributing factors for constipation in patients with gastrointestinal cancer: a multicenter cross-sectional study in China.
Constipation
Gastrointestinal neoplasms
Risk assessment
Risk factors
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
20
02
2022
accepted:
23
06
2022
pubmed:
3
7
2022
medline:
28
9
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
The purpose of this study is to determine the risk of constipation and to identify the significant risk factors for constipation in patients with gastrointestinal cancer using the Chinese version of the constipation risk assessment scale (CRAS-C), as well as to explore the complementary constipation risk factors in patients with gastrointestinal cancer, to improve the specificity of the CRAS-C in this population, and finally to provide a theoretical basis for constipation prevention. A cross-sectional study involving multiple centers was conducted. A total of 190 patients with gastrointestinal cancer completed surveys that included demographic information, defecation habits, and the CRAS-C. The mean, SD, median, maximum, minimum, frequency, and percentage were used as indicators for the constipation risk and significant risk factors. The t test and Chi-square tests were used to analyze constipation indicators in patients with gastrointestinal cancer. The mean (SD) age of the 190 participants was 61.68 (12.35) years. The total CRAS-C mean (SD) score was 13.22 (4.69). Fifty-one patients (26.8%) scored lower than 11, who were at the low-risk level of constipation. One hundred thirty-nine patients (73.2%) scored 11 or above, who were at the high-risk level of constipation. The top 10 factors were insufficient liquid intake (81.1%), failure to consume bran products daily (78.9%), insufficient fiber intake (77.9%), antiemetics (74.7%), cytotoxic chemotherapy (52.6%), colorectal/abdominal diseases (42.6%), female (35.3%), opioid analgesics(26.8%), calcium channel blockers (16.3%), and endocrine disorders (14.2%). Chi-square test showed that constipating for most of the past 3 months, ascites and ECOG score were complementary constipation risk factors in gastrointestinal cancer patients. The findings indicate that most gastrointestinal cancer patients were at a high risk of constipation. There are also several complementary constipation risk factors, and CRAS-C can be further revised in future studies to make it more specific in gastrointestinal cancer patients. Integrating CRAS into the pathway of constipation management, carrying out constipation risk screening for hospitalized cancer patients, and building systematic constipation prevention plan based on risk assessment are important to reduce the incidence of constipation in patients with gastrointestinal cancer and improve the quality of life.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The purpose of this study is to determine the risk of constipation and to identify the significant risk factors for constipation in patients with gastrointestinal cancer using the Chinese version of the constipation risk assessment scale (CRAS-C), as well as to explore the complementary constipation risk factors in patients with gastrointestinal cancer, to improve the specificity of the CRAS-C in this population, and finally to provide a theoretical basis for constipation prevention.
RESEARCH DESIGN AND METHODS
METHODS
A cross-sectional study involving multiple centers was conducted. A total of 190 patients with gastrointestinal cancer completed surveys that included demographic information, defecation habits, and the CRAS-C. The mean, SD, median, maximum, minimum, frequency, and percentage were used as indicators for the constipation risk and significant risk factors. The t test and Chi-square tests were used to analyze constipation indicators in patients with gastrointestinal cancer.
RESULTS
RESULTS
The mean (SD) age of the 190 participants was 61.68 (12.35) years. The total CRAS-C mean (SD) score was 13.22 (4.69). Fifty-one patients (26.8%) scored lower than 11, who were at the low-risk level of constipation. One hundred thirty-nine patients (73.2%) scored 11 or above, who were at the high-risk level of constipation. The top 10 factors were insufficient liquid intake (81.1%), failure to consume bran products daily (78.9%), insufficient fiber intake (77.9%), antiemetics (74.7%), cytotoxic chemotherapy (52.6%), colorectal/abdominal diseases (42.6%), female (35.3%), opioid analgesics(26.8%), calcium channel blockers (16.3%), and endocrine disorders (14.2%). Chi-square test showed that constipating for most of the past 3 months, ascites and ECOG score were complementary constipation risk factors in gastrointestinal cancer patients.
CONCLUSION
CONCLUSIONS
The findings indicate that most gastrointestinal cancer patients were at a high risk of constipation. There are also several complementary constipation risk factors, and CRAS-C can be further revised in future studies to make it more specific in gastrointestinal cancer patients. Integrating CRAS into the pathway of constipation management, carrying out constipation risk screening for hospitalized cancer patients, and building systematic constipation prevention plan based on risk assessment are important to reduce the incidence of constipation in patients with gastrointestinal cancer and improve the quality of life.
Identifiants
pubmed: 35779131
doi: 10.1007/s00520-022-07255-4
pii: 10.1007/s00520-022-07255-4
doi:
Substances chimiques
Analgesics, Opioid
0
Antiemetics
0
Calcium Channel Blockers
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
8119-8127Subventions
Organisme : Peking University Cancer Hospital's Science Foundation
ID : 2021-19
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WQ, He J (2015) Report of cancer epidemiology in China, 2015. Chin J Oncol 41(1):19–28. https://doi.org/10.3760/cma.j.issn.0253-3766.2019.01.008
doi: 10.3760/cma.j.issn.0253-3766.2019.01.008
Davies A, Leach C, Caponero R, Dickman A, Fuchs D, Paice J, Emmanuel A (2020) MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer 28(1):23–33. https://doi.org/10.1007/s00520-019-05016-4
doi: 10.1007/s00520-019-05016-4
pubmed: 31396746
Zhou XR (2014) An observation study of constipation in patients with cancer during chemotherapy. Int J Nur 33(7):1676–1679. https://doi.org/10.3760/cma.j.issn.1673-4351,2014.07.046
doi: 10.3760/cma.j.issn.1673-4351,2014.07.046
Li R, Zhao YZ, Lu P (2011) Investigation and analysis of constipation in 630 patients with cancer. Chin J Gerontol 31(9):1671–1672. https://doi.org/10.3969/j.issn.1005-9202,2011.09.086
doi: 10.3969/j.issn.1005-9202,2011.09.086
Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, Gootjes JRG, Nabal M, Noguera A, Ripamonti C, Zucco F, Zuurmond WWA, on behalf of the European Consensus Grp C (2008) The management of constipation in palliative care: clinical practice recommendations. Palliat Med 22(7):796–807. https://doi.org/10.1177/0269216308096908
doi: 10.1177/0269216308096908
pubmed: 18838491
Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgathe C, Scotte F, Ripamonti CI (2018) Diagnosis, assessment and management of constipation in advanced cancer: ESMO clinical practice guidelines. Ann Oncol 29 Suppl 4:iv111–iv125. https://doi.org/10.1093/annonc/mdy148
doi: 10.1093/annonc/mdy148
pubmed: 32169221
Richmond JP, Wright ME (2004) Review of the literature on constipation to enable development of a constipation risk assessment scale. J Orthop Nurs 8(4):192–207. https://doi.org/10.1016/j.cein.2004.05.001
doi: 10.1016/j.cein.2004.05.001
Richmond JP, Wright ME (2006) Development of a constipation risk assessment scale. J Orthop Nurs 10(4):186–197. https://doi.org/10.1016/j.joon.2006.08.001
doi: 10.1016/j.joon.2006.08.001
Ma XX, Lu Q, Lu YH, Yu WH, Kang DQ, Zhao YY, Xing PB, Guo RX, Wang Y (2021) Validation of the constipation risk assessment scale (CRAS) in Chinese cancer patients. Eur J Oncol Nurs 50:101895–101895. https://doi.org/10.1016/j.ejon.2021.101895
doi: 10.1016/j.ejon.2021.101895
pubmed: 33461155
Suresh KP, Chandrashekara S (2012) Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci 5(1):7–13. https://doi.org/10.4103/0974-1208.97779
doi: 10.4103/0974-1208.97779
pubmed: 22870008
pmcid: 3409926
Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920–924. https://doi.org/10.3109/00365529709011203
doi: 10.3109/00365529709011203
pubmed: 9299672
Abarado C (2014) Improving constipation management in oncology: a unit-level implementation of constipation risk assessment scale (2009–2010). J Geriatr Oncol 5:S67–S67. https://doi.org/10.1016/j.jgo.2014.09.121
doi: 10.1016/j.jgo.2014.09.121
Palliative Care. Available from: https://www.ons.org/make-difference/ons-center-advocacy-and-health-policy/position-statements/palliative-care-people . Accessed 21 Feb 2022
Arthur J, Hui D (2018) Safe opioid use: management of opioid-related adverse effects and aberrant behaviors. Hematol Oncol Clin N Am 32(3):387–403. https://doi.org/10.1016/j.hoc.2018.01.003
doi: 10.1016/j.hoc.2018.01.003
Neefjes E, Hanneke V, van der Vorst MJDL, Oever DT, Van D, Beeker A, Rhodius CA, Van D, Berkhof J, Verheul H (2019) Optimal treatment of opioid induced constipation in daily clinical practice – an observational study. BMC Palliat Care 18(1):31. https://doi.org/10.1186/s12904-019-0416-7
doi: 10.1186/s12904-019-0416-7
pubmed: 30922276
pmcid: 6439982
Rogers B, Ginex PK, Anbari A, Hanson BJ, Morgan RL (2020) ONS guidelines for opioid-induced and non–opioid-related cancer constipation. Oncol Nurs Forum 47(6):671–691. https://doi.org/10.1188/20.ONF.671-691
doi: 10.1188/20.ONF.671-691
pubmed: 33063786
National Comprehensive Cancer Network. NCCN guidelines version 1.2019 adult cancer pain. Available from: https://www.nccn.org/professionals/physiciangls/default.aspx#age . Accessed 21 Feb 2022
Wang SY (2018) Retrospective analysis of risk factors and preventive treatment of opioid-induced constipation in patients with cancer pain. ShanDong University
Mcmillan SC, Tofthagen C, Small B, Karver S, Craig D (2013) Trajectory of medication-induced constipation in patients with cancer. Oncol Nurs Forum 40(3):E92–E100. https://doi.org/10.1188/13.ONF.E92-E100
doi: 10.1188/13.ONF.E92-E100
pubmed: 23615153
pmcid: 5385997
Larkin PJ, Cherny NI, Carpia DL, Guglielmo M, Ostgathe C, Scotté F, Ripamonti CI (2018) Diagnosis, assessment and management of constipation in advanced cancer: ESMO clinical practice guidelines. Ann Oncol 29(Suppl. 4):iv111–iv125. https://doi.org/10.3761/j.issn.0254-1769.2012.03.039
doi: 10.3761/j.issn.0254-1769.2012.03.039
pubmed: 32169221
Duffy J, Zernike W (1997) Development of a constipation risk assessment scale. Int J Nurs Pract 5(2):106–109. https://doi.org/10.1111/j.1440-172X.1997.tb00111.x
doi: 10.1111/j.1440-172X.1997.tb00111.x
Zhe H (2016) The assessment and management of constipation among patients with advanced cancer in a palliative care ward in China: a best practice implementation project. JBI Database System Rev Implement Rep 14(5):295–309. https://doi.org/10.11124/jbisrir-2016-002631
doi: 10.11124/jbisrir-2016-002631
pubmed: 27532474